<DOC>
	<DOCNO>NCT02544217</DOCNO>
	<brief_summary>Mitochondrial Diseases rare progressive , multi-system , often early fatal disorder affect child adult . KH176 novel chemical entity currently development treatment inherit mitochondrial disease , include MELAS ( Mitochondrial Encephalomyopathy , Lactic acidosis , Stroke-like episode ) , Leigh 's Disease LHON ( Leber 's Hereditary Optic Neuropathy ) . KH176 potent intracellular redox modulate agent target reactive oxygen specie important pathogenesis disorder mitochondrial oxidative phosphorylation . After demonstrate favourable safety profile pre-clinical testing , safety , tolerability pharmacokinetic pharmacodynamic characteristic compound evaluate healthy male subject trial</brief_summary>
	<brief_title>A Dose-escalating Clinical Trial With KH176</brief_title>
	<detailed_description />
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Leigh Disease</mesh_term>
	<criteria>Healthy assess medical history , physical examination , Vital Signs , Clinical Laboratory , ECG Allergies , Concomitant medication , concomitant disease , relevant surgery , recent blood donation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>